These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3838399)

  • 41. Effect of molsidomine on cardiac preload, coronary artery diameter, and coronary resistance.
    Bassenge E; Pohl U
    Am Heart J; 1985 Mar; 109(3 Pt 2):627-30. PubMed ID: 3838398
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molsidomine prevents post-ischaemic ventricular fibrillation in dogs.
    Cano JP; Guillen JC; Jouve R; Langlet F; Puddu PE; Rolland PH; Serradimigni A
    Br J Pharmacol; 1986 Aug; 88(4):779-89. PubMed ID: 3755634
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Long-term clinical and hemodynamic results of the treatment of refractory cardiac failure with molsidomine].
    Kulas A; Escudier B; Hannachi N; Kolski H; Witchitz S; Acar J
    Arch Mal Coeur Vaiss; 1984 Jan; 77(1):92-9. PubMed ID: 6422898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Cellular mechanism of action of molsidomine. Bioinduction of prostacyclin].
    Poincelot B; Russo-Marie F
    Ann Cardiol Angeiol (Paris); 1983 Dec; 32(8):535-7. PubMed ID: 6421223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The metabolism of [14C]N-ethoxycarbonyl-3-morpholinosydnonimine (molsidomine) in laboratory animals.
    Wilson ID; Watson KV; Troke J; Illing HP; Fromson JM
    Xenobiotica; 1986 Dec; 16(12):1117-28. PubMed ID: 3798959
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Hemodynamic effect of molsidomine in acute administration and as a long-term medication].
    Osterspey A; Jansen W; Tauchert M; Schell U; Fuchs M; Hombach V; Hilger HH
    Med Welt; 1983 Apr; 34(17):523-8. PubMed ID: 6408341
    [No Abstract]   [Full Text] [Related]  

  • 47. Prevention with molsidomine of coronary artery spasm caused by alkalosis.
    Weber S; Kahan A; Pailleret JJ; Guérin F; Degeorges M
    Am Heart J; 1985 Mar; 109(3 Pt 2):704-7. PubMed ID: 3838408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of molsidomine and its metabolite SIN-1 on coronary vessel tone, platelet aggregation, and eicosanoid formation in vitro--inhibition of 12-HPETE biosynthesis.
    Darius H; Ahland B; Rücker W; Klaus W; Peskar BA; Schrör K
    J Cardiovasc Pharmacol; 1984; 6(1):115-21. PubMed ID: 6199592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs.
    Ishizaki T; Chiba K; Suganuma T; Sasaki T; Kamiyama H; Nakano H
    J Pharm Sci; 1984 Apr; 73(4):494-8. PubMed ID: 6233416
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of nicorandil.
    Frydman AM; Chapelle P; Diekmann H; Bruno R; Thebault JJ; Bouthier J; Caplain H; Ungethuem W; Gaillard C; Le Liboux A
    Am J Cardiol; 1989 Jun; 63(21):25J-33J. PubMed ID: 2525322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine.
    Ahr HJ; Krause HP; Siefert HM; Suwelack D; Weber H
    Arzneimittelforschung; 1988 Aug; 38(8):1093-8. PubMed ID: 3196402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Double-blind, randomized, placebo-controlled study of molsidomine in patients with stable effort angina receiving beta-blocker therapy with atenolol.
    De Backer GG; Derese A
    Am Heart J; 1985 Mar; 109(3 Pt 2):678-81. PubMed ID: 3883735
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of substituted sydnonimines on coronary smooth muscle relaxation and cyclic guanosine monophosphate levels.
    Rinaldi G; Cingolani H
    Circulation; 1983 Dec; 68(6):1315-20. PubMed ID: 6315260
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Hypotension induced by molsidomine or trinitroglycerin].
    Dassier P; Blanloeil Y; Pinaud M; Bodin D; Vandeville B
    Cah Anesthesiol; 1985; 33(4):309-13. PubMed ID: 3931864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanism of vasodilation by molsidomine.
    Kukovetz WR; Holzmann S
    Am Heart J; 1985 Mar; 109(3 Pt 2):637-40. PubMed ID: 2983523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of molsidomine on regional contraction and global function of the left ventricle.
    Stauch M; Haerer W; Rogg-Dussler G; Sigel H; Adam WE
    Am Heart J; 1985 Mar; 109(3 Pt 2):653-8. PubMed ID: 3838402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Hemodynamic effects of molsidomine in chronic congestive heart failure].
    Humar F; Maras P; Musitelli G; Camerini F
    G Ital Cardiol; 1986 May; 16(5):427-32. PubMed ID: 3755413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hemodynamic effects of molsidomine on weight sustaining isometric exercise in patients with ischemic heart disease.
    Tsujibayashi T; Niwa A; Taniguchi K; Takeuchi J
    Bull Tokyo Med Dent Univ; 1985 Dec; 32(4):163-7. PubMed ID: 3865742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolism of flecainide.
    Conard GJ; Ober RE
    Am J Cardiol; 1984 Feb; 53(5):41B-51B. PubMed ID: 6364769
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
    Bramer SL; Forbes WP; Mallikaarjun S
    Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.